CSCID (Cosciens Biopharma) Ending Cash Position: $5.01 Mil (As of Mar. 2026)


CSCID Cosciens Biopharma Inc CSCID
61 GF Score
Price $7.00
GF Value $6.57
Valuation Fairly Valued
! 6 Warning Signs
View Full Analysis

What is Cosciens Biopharma Ending Cash Position?

Cosciens Biopharma CSCID -68.03% 61 Ending Cash Position is $5.01 Mil as of Mar. 2026. GuruFocus rates CSCID with a GF Score™ of 61/100 and a GF Value™ of $6.57 (Fairly Valued). The stock has 6 warning signs investors should review.

Cosciens Biopharma's Ending Cash Position for the quarter that ended in Mar. 2026 was $5.01 Mil.

Cosciens Biopharma's quarterly Ending Cash Position declined from Sep. 2025 ($8.52 Mil) to Dec. 2025 ($7.31 Mil) and declined from Dec. 2025 ($7.31 Mil) to Mar. 2026 ($5.01 Mil).

Cosciens Biopharma's annual Ending Cash Position increased from Dec. 2023 ($6.68 Mil) to Dec. 2024 ($16.39 Mil) but then declined from Dec. 2024 ($16.39 Mil) to Dec. 2025 ($7.31 Mil).

Cosciens Biopharma Ending Cash Position Related Terms

Cosciens Biopharma Ending Cash Position Historical Data

* Premium members only.

The historical data trend for Cosciens Biopharma's Ending Cash Position can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Cosciens Biopharma Ending Cash Position Chart

Cosciens Biopharma Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Ending Cash Position
Get a 7-Day Free Trial Premium Member Only Premium Member Only 6.10 10.19 6.68 16.39 7.31

Cosciens Biopharma Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Ending Cash Position Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 13.76 9.33 8.52 7.31 5.01
CSCID
61GF Score
Cosciens Biopharma Inc CSCID
Ending Cash Position is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Cosciens Biopharma Ending Cash Position Calculation

Ending Cash Position is the cash and cash equivalents balance at the end of the accounting period, as indicated on the Cash Flow statement. It is equal to the Beginning Cash Position plus the Net Change in Cash.

Cosciens Biopharma's Ending Cash Position for the fiscal year that ended in Dec. 2025 is calculated as

Ending Cash Position= Beginning Cash Position+Net Change in Cash
=16.393+-9.086
=7.31

Cosciens Biopharma's Ending Cash Position for the quarter that ended in Mar. 2026 is calculated as

Ending Cash Position=Beginning Cash Position+Net Change in Cash
=7.307+-2.302
=5.01

Frequently Asked Questions Learn more about Ending Cash Position →
What does a Ending Cash Position of $5.01 Mil mean?
Cosciens Biopharma (CSCID) has a Ending Cash Position of $5.01 Mil as of Mar. 2026. Ending Cash Position is the cash and cash equivalents balance at the end of the accounting period, as indicated on the Cash Flow statement. View historical data on Cosciens Biopharma and its competitors.
Is Cosciens Biopharma's Ending Cash Position too high?
Cosciens Biopharma's current Ending Cash Position is $5.01 Mil. Overall, Cosciens Biopharma has a GF Score™ of 61/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Cosciens Biopharma's Ending Cash Position compare to VRTX and REGN?
Cosciens Biopharma's Ending Cash Position of $5.01 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Ending Cash Position for a Biotechnology company?
A good Ending Cash Position depends on the Biotechnology industry context. However, Ending Cash Position should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Ending Cash Position mean?
A high Ending Cash Position can signal that a stock is expensive relative to its fundamentals. Ending Cash Position is the cash and cash equivalents balance at the end of the accounting period, as indicated on the Cash Flow statement. View historical data on Cosciens Biopharma and its competitors. Cosciens Biopharma's current Ending Cash Position is $5.01 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Cosciens Biopharma stock overvalued right now?
Based on GuruFocus' analysis, Cosciens Biopharma (CSCID) is currently considered Fairly Valued. The stock's GF Value™ is $6.57, compared to a current price of $7.00 — trading 6.5% above its estimated fair value. The current Ending Cash Position is $5.01 Mil. Cosciens Biopharma's overall GF Score™ is 61/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Ending Cash Position calculated?
Ending Cash Position is calculated from a company's financial statements. For Cosciens Biopharma (CSCID), the current Ending Cash Position is $5.01 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Cosciens Biopharma (CSCID) Overvalued in 2026?

Based on GuruFocus' analysis, Cosciens Biopharma stock appears to be overvalued. The current stock price of $7.00 is trading 6.5% above its estimated GF Value™ of $6.57. GuruFocus considers Cosciens Biopharma to be Fairly Valued.

Key valuation signals for CSCID:

  • Ending Cash Position: $5.01 Mil
  • GF Value™: $6.57 vs. price of $7.00 (6.5% above fair value)
  • GF Score™: 61/100 with 6 warning signs

No single metric tells the full story. See the CSCID stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Cosciens Biopharma Business Description

Other Exchanges ET8:GermanyCSCI:Canada
Address C/o Borden Ladner Gervais Llp, Suite 3400, 22 Adelaide Street West, Toronto, ON, CAN, M5H 4E3
Cosciens Biopharma Inc is a biopharmaceutical company developing and commercializing pharmaceutical and diagnostic products and active ingredients for the healthcare and cosmetics industries. It operates through two segments: Active Ingredient and Biopharmaceutical. The Active Ingredient segment, which generates maximum revenue, focuses on plant-based ingredients derived from oats and other renewable resources, including oat beta glucan, oat oil, and avenanthramides. The Biopharmaceutical segment focuses on the development and commercialization of therapeutics and diagnostic tests, including its product Macrilen, and advancing a pre-clinical pipeline targeting unmet medical needs, particularly in rare or orphan indications. It operates in Canada, Germany, the United States, and Austria.
61GF Score

Get the complete analysis for CSCID

Ending Cash Position is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$7.00
Price
$6.57
GF Value